Alector, Inc. (ALEC)
NASDAQ: ALEC · Real-Time Price · USD
1.490
+0.030 (2.05%)
At close: Dec 12, 2025, 4:00 PM EST
1.480
-0.010 (-0.67%)
After-hours: Dec 12, 2025, 7:30 PM EST
Alector Employees
Alector had 238 employees as of December 31, 2024. The number of employees decreased by 6 or -2.46% compared to the previous year.
Employees
238
Change (1Y)
-6
Growth (1Y)
-2.46%
Revenue / Employee
$290,118
Profits / Employee
-$452,672
Market Cap
162.64M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 238 | -6 | -2.46% |
| Dec 31, 2023 | 244 | -29 | -10.62% |
| Dec 31, 2022 | 273 | 65 | 31.25% |
| Dec 31, 2021 | 208 | 37 | 21.64% |
| Dec 31, 2020 | 171 | 50 | 41.32% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ALEC News
- 1 day ago - Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer - GlobeNewsWire
- 5 days ago - Alector, Inc. (ALEC) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript - Seeking Alpha
- 12 days ago - Alector to Participate in the Bank of America CNS Therapeutics Conference - GlobeNewsWire
- 18 days ago - ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewsWire
- 5 weeks ago - Alector Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce - Benzinga
- 7 weeks ago - Alector Announces Results from its Phase 3 Clinical Trial of Potential FTD-GRN Therapeutic - GlobeNewsWire
- 7 weeks ago - Alector shares plunge after dementia drug fails to slow disease progression - Reuters